북미 익막약 시장 – 2029년까지의 산업 동향 및 예측

북미 익막약 시장 분석 및 통찰력

익막은 눈꺼풀 틈새 안의 변연 결막에서 시작하여 각막으로 진행되는 흔한 안구 표면 병변입니다. 이는 "날개"를 의미하는 그리스어 pterygos에서 따온 이름입니다. 이 병변은 측두엽보다 비강 변연에서 더 자주 발생하며 특징적인 날개 모양이 있습니다. 자외선 노출은 익막의 발생과 밀접한 관련이 있습니다. 자외선 노출 병력이 있거나 적도에 더 가깝게 사는 사람은 발병률이 더 높습니다(야외 작업). 특정 연구에 따르면 남성이 여성보다 발병률이 다소 높은데, 이는 자외선 노출률이 더 높기 때문일 수 있습니다.

발적, 염증, 눈 모양 변화를 일으킬 수 있습니다. 난시를 일으킬 수 있으며, 이는 시력을 흐리게 만들 수 있습니다. 눈 앞부분을 덮는 희끄무레하거나 분홍빛 성장이 생길 수 있습니다. 한쪽 또는 양쪽 눈에 영향을 미칠 수 있습니다.

익막염은 전체 눈 검사를 통해 눈의 앞쪽 부분을 현미경으로 검사하여 진단하며, 눈의 흰자위에서 각막에 조직이 자라는 모습을 통해 진단합니다.

Data Bridge Market Research에 따르면 북미 익막약 시장이 2022년부터 2029년까지의 예측 기간 동안 연평균 성장률 5.8%로 성장할 것으로 분석되었습니다.

 North America Pterygium Drug Market Dynamics

Drivers

• Rise in incidences and prevalence of ophthalmic disorders

According to data published in the National Library of Medicine (National Center for Biotechnology Information) in 2021, the prevalence rates vary in different places. It is most abundant in Cameron's "pterygium belt," which runs between 37° north and south of the equator.

The most common causes of pterygium include long-term exposure to ultraviolet (UV) light from the sun (the most common cause) and eye irritation caused by hot, dry weather, wind, and dust. The affirmative factors state that this is the major driver for the North America pterygium drugs market.

• Rise in the geriatric population

With the growing geriatric population across the globe, the prevalence of ophthalmic diseases with severe ocular pain is also growing. According to data provided published in "Global Prevalence of Blindness and Distance and Near Vision Impairment in 2020: progress towards the Vision 2020 targets and what the future holds" by "The Association for Research in Vision and Ophthalmology" (ARVO) estimated 41.9 million people were blind.

With the growing population, the pressure on the healthcare system is increasing. The demand for care and services is rising to treat the problem of Ophthalmol disorder, including pterygium. Therefore, the increasing geriatric population is a great opportunity for the North America pterygium drug market.

Opportunities

• Programs and initiatives to reduce the burden of eye diseases

The International agency to prevent blindness has launched several programs and initiatives with well-reputed NGOs and corporates to spread awareness and reduce the burden of eye diseases.

For instance,

• International Agency endorses our Children's Vision and an initiative co-founded by the Brien Holden Vision Institute and the Vision For Life fund (created by Essilor) for the Prevention of Blindness (IAPB)

Restraints/Challenges

• High cost of eye treatment and medication

The growing prevalence of various ophthalmic disorders has also increased the necessity for timely treatments. However, the treatments and proper medication for ophthalmology disorders are not very cheap. Recent studies show that the price of topical steroids price is increasing in the past few years. Even though some topical ophthalmic steroids like prednisolone are mildly cheap, other advanced medications and eye drops are still expensive.

The North America pterygium drug market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the pterygium drug market, contact Data Bridge Market Research for an Analyst Brief. Our team will help you make an informed market decision to achieve market growth.

Patient Epidemiology Analysis

The prevalence of ophthalmic disorders keeps showing a surge in growth due to the rise in chemical industries and pollution worldwide. Chemical burns and flash burns cause significant and severe ocular pain due to irritations over the eye surface.

According to data published in the National Library of Medicine (National Center for Biotechnology Information) in 2021, the prevalence rates vary in different places. It is most abundant in Cameron's "pterygium belt," which runs between 37° north and south of the equator. Pterygium prevalence has been reported to range from 0.3 to 29% worldwide.

The North America pterygium drug market also provides detailed market analysis for patient analysis, prognosis, and cures. Prevalence, incidence, mortality, and adherence are some data variables available in the report. Direct or indirect impact analysis of epidemiology to the market growth are analyzed to create a more robust and cohot multivariate statistical model for forecasting the market in the growth period.

Post-COVID-19 Impact on North America Pterygium Drug Market

COVID-19 has negatively affected the market. Lockdowns and isolations during pandemics complicate disease management and medication adherence. The lack of access to healthcare facilities for routine treatment and medication administration will further impact the market.

Recent Development

• In January 2022, Alcon announced the launch of Systane complete preservative-free lubricant eye drops in Europe. The product works to provide all-in-one dry eye relief with one drop by hydrating the layers of the tear film. This has helped the company to increase its product portfolio

North America Pterygium Drug Market Scope

The North America pterygium drug market is categorized into eight notable segments based on disease type, stages, treatment, and formulation, mode of purchase, population type, end-user, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Disease Type

• Progressive Pterygium
• Atrophic Pterygium

Based on disease, the North America pterygium drug market is segmented into progressive pterygium and atrophic pterygium.

Stages

• Stage 1
• Stage 2
• Stage 3

Based on stages, the North America pterygium drug market is segmented into stage 1, stage 2, stage 3,

Treatment

• Artificial Tears/Topical Lubricants
• Steroid Eye Drops

Based on treatment, the North America pterygium drug market is segmented into artificial tears/topical lubricants and steroid eye drops.

Formulation

• Eye Drops
• Eye Ointments
• Others

Based on formulation, the North America pterygium drug market is segmented into eye drops, eye ointments, and others.

Mode of Purchase

• Prescription
• Over the Counter (OTC)

Based on the mode of purchase, the North America pterygium drug market is segmented into prescription and over-the-counter (OTC).

Population Type

• Geriatric
• Adults

Based on population type, the North America pterygium drug market is segmented into geriatric and adults.

End-User

• Hospitals
• Specialty Clinics
• Home Healthcare
• Others

Based on end-user, the North America pterygium drug market is segmented into hospitals, specialty clinics, home healthcare, and others.

Distribution Channel

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies
• Others

Based on distribution channels, the North America pterygium drug market is segmented into retail pharmacies, hospital pharmacies, and online pharmacies.

North America Pterygium Drug Market Regional Analysis/Insights

The North America pterygium drug market is analyzed, and market size insights and trends are provided by country, disease type, stages, treatment, and formulation, mode of purchase, population type, end-user, and distribution channel as referenced above.

The countries covered in the North America pterygium drug market report are the U.S., Canada, and Mexico.

The North America pterygium drug market is expected to grow due to the presence of big market players in the region and an established healthcare system. The U.S. is expected to dominate the North America pterygium drug market in terms of market share and market revenue. It will continue to flourish its dominance during the forecast period. This is due to the high prevalence of disease in the region.

The country section of the report also provides individual market-impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of North America brands and their challenges faced due to high competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and North America Pterygium Drug Market Share Analysis

북미 익막약 시장 경쟁 구도는 경쟁자에 대한 세부 정보를 제공합니다. 세부 정보에는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 유럽의 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우위가 포함됩니다. 위에 제공된 데이터 포인트는 익막약 시장과 관련된 회사의 초점에만 관련이 있습니다.

북미 익막증 약물 시장의 주요 기업으로는 Johnson & Johnson Services, Inc., Novartis AG, Akorn Operating Company LLC, Bausch & Lomb Incorporated, AbbVie Inc., Prestige Consumer Healthcare Inc., Théa Laboratories, Wellona Pharma, Bayer AG, Zydus Group, Amneal Pharmaceuticals LLC, OASIS Medical, Alcon, Santen Pharmaceutical Co., Ltd. 등이 있습니다.

연구 방법론

데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석 및 추정됩니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 기본(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 이 외에도 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 회사 시장 점유율 분석, 측정 표준, 북미 대 지역 및 공급업체 점유율 분석이 포함됩니다. 추가 문의 사항이 있는 경우 분석가에게 전화를 요청하십시오.

SKU-68696